Download PDF
Pharmacopsychiatry 2003; 36(5): 181-186
DOI: 10.1055/s-2003-43047
Original Paper
© Georg Thieme Verlag Stuttgart · New York

Acute Effects of Cholecystokinin Tetrapeptide on Brain Stem Auditory Evoked Potentials in Healthy Volunteers

T. Gunnarsson1 , C. Mahoney2 , J. Shlik3 , J. Bradwejn4 , V. Knott4
  • 1Department of Neuroscience and Locomotion, Psychiatric Section, University Hospital, Linkoping, Sweden
  • 2Royal Ottawa Hospital, Ottawa, Ontario, Canada
  • 3Department of Psychiatry, University of Tartu, Estonia
  • 4Department of Psychiatry, University of Ottawa/Royal Ottawa Hospital and Institute of Mental Health Research, Ottawa, Ontario, Canada
Further Information

Publication History

Received: 11.2.2002 Revised: 24.4.2002

Accepted: 15.10.2002

Publication Date:
18 May 2004 (online)

Also available at
    Permissions and Reprints

This study investigated the effects of continuous slow intravenous infusion of cholecystokinin tetrapeptide (CCK-4) on brain stem auditory evoked potentials (BSAEP) in healthy subjects. Twenty-four subjects, 15 females and 9males, were assigned to infusion with either placebo or CCK-4 in a randomized, double-blind, parallel group design. BSAEPs, mood, physical symptoms, and vital signs were assessed once before infusion and at 10 min and 40 min after the onset of infusion. In the 16 subjects (N = 8, CCK-4; N = 8, placebo) CCK-4, compared to placebo, delayed peak I latency during early infusion, slowed the latencies of peaks III and V, and decreased the amplitude of peak III throughout the infusion. No significant treatment differences were observed with respect to symptoms, mood, or cardiovascular measures. These preliminary findings suggest that CCK-4 may interfere with information processing in the brain stem auditory pathways and that prolonged intravenous CCK-4 administration may be a useful challenge paradigm for investigating CCK’s modulatory role on brain stem mechanisms mediating anxiety and panic in humans.

Key words

Cholecystokinin - CCK-4 - brain stem auditory evoked potentials - anxiety, panic

References

  • 1 Abelson J L, Nesse R M. Pentagastrin infusions in patients with panic disorder. I: Symptoms and cardiovascular responses.  Biol Psychiatry. 1994;  36 73-83
    CrossrefPubMedGoogle Scholar
  • 2 Albus M. Cholecystokinin.  Prog Neuro-Psychopharmacol and Biol Psychiatry. 1988;  12 S5-21
    PubMedGoogle Scholar
  • 3 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition ed Washington, D.C; American Psychiatric Association 1994
    Google Scholar
  • 4 Bobillier P, Seguin S, Petitjean F, Salvert D, Touret M, Jouvet M. The raphe nuclei of the cat brainstem: a topographical atlast of their efferent projections as revealed by autoradiography.  Brain Res. 1976;  113 449-486
    CrossrefPubMedGoogle Scholar
  • 5 Bourin M, Malinge M, Guitton B. Provocative agents in panic disorder.  Therapie. 1995;  50 301-306
    PubMedGoogle Scholar
  • 6 Bradweyn J, Kosycki D, Meterissian G. Cholccystokinin-tetrapeptide induces panic attacks in patients with panic disorder.  Can J Psychiatry. 1990;  35 83-85
    PubMedGoogle Scholar
  • 7 Bradwejn J, Koszycki D, Bourin M. Dose ranging study of the effects of cholecystokinin in healthy volunteers.  J Psychiatry Neurosci. 1991;  16 91-95
    PubMedGoogle Scholar
  • 8 Bradwejn J, Koszycki D, Payeur R. Cholecystokinin-tetrapeptide: A provocation agent for research in panic disorders?. In Briley M, Files S (eds) New Concepts in anxiety. MacMillan Press London; 1991
    Google Scholar
  • 9 Bradwejn J, Koszycki D, Shriqui C. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder.  Arch Gen Psychiatry. 1991;  7 603-610
    PubMedGoogle Scholar
  • 10 Bradwejn J, Koszycki D. The cholecystokinin hypothesis of anxiety and panic disorder. In Reeve JR Jr, Solomon TE, Go VL (eds) Cholecystokinin. The New York Academy of Sciences New York, NY; 1994
    Google Scholar
  • 11 Branchereau R, Champagnat J, Roques B, Denavit-Saubie M. CCK modulates inhibitory synaptic transmission in the solitary complex through CCK B sites.  Neuroeport. 1992;  3 909-912
    PubMedGoogle Scholar
  • 12 Caspary D, Havey D, Faingold C. Effects of microiontophoretically applied glycine and GABA on neuronal response pattern in the cochlear nuclei.  Brain Res. 1979;  172 179-185
    CrossrefPubMedGoogle Scholar
  • 13 Charney D S, Heninger G R, Jatlow P. Increased anxiogenic effects of caffeine in panic disorders.  Arch Gen Psychiatry. 1985;  42 233-243
    PubMedGoogle Scholar
  • 14 Charney D S, Woods S W, Goodman W K, Heninger G R. Neurobiological mechanisms of panic anxiety: biochemical and behavioral correlates of yohimbine-induced panic attacks.  Am J Psychiatry. 1987;  144 1030-1036
    PubMedGoogle Scholar
  • 15 Charney D S, Woods S W, Krystal J H, Nagy L M, Heninger G R. Noradrenergic neuronal dysregulation in panic disorder: the effects of intravenous yohimbine and clonidine in panic disorder patients.  Acta Psychiat Scand. 1992;  86 273-282
    PubMedGoogle Scholar
  • 16 Chiappa K. Evoked potentials in clinical medicine, Lippincott - Raven Publishers (3rd Ed). Philadelphia; 1997
    Google Scholar
  • 17 Coplan J D, Lydiard R B. Brain circuits in panic disorder.  Biol Psychiatry. 1998;  44 1264-1276
    CrossrefPubMedGoogle Scholar
  • 18 Crawley J N, Corwin R L. Biological actions of cholecystokinin.  Peptides. 1994;  15 731-755
    CrossrefPubMedGoogle Scholar
  • 19 Crawley J N. Interactions between cholecystokinin and other neurotransmitter systems. In Bradwejn J, Vasar E (eds) Cholecystokinin and anxiety: from neuron to behavior. Springer Verlag Austin; 1995
    Google Scholar
  • 20 de Montigny C. Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers.  Arch Gen Psychiatry. 1989;  46 511-517
    PubMedGoogle Scholar
  • 21 Derogatis L, Lipman R, Richels K. The Hopkins Symptom Checklist (HSCL): a measure of primary symptom dimensions. In Pichot P (ed) Psychological measurement: modern problems in pharmacopsychiatry. Karger Basel, Switzerland; 1979
    Google Scholar
  • 22 Don M, Eggermont J. Analysis of the click-evoked brainstem potentials in man using high-pass noise masking.  J Accost Soc Am. 1978;  63 1084-1092
    PubMedGoogle Scholar
  • 23 Epstein C M. The use of brain stem auditory evoked potentials in the evaluation of the central nervous system.  Neurol Clin. 1998;  6 771-790
    PubMedGoogle Scholar
  • 24 Eybalin M, Parnaud C, Geffard M, Pujoi R. Immunoclectron miscroscopy identiifes several types of GABA- contaning efferent synapses in the guinea-pig organ of Corti.  Neurosci. 1988;  24 29-38
    CrossrefPubMedGoogle Scholar
  • 25 Fex J, Altschuler R, Kachar B, Wenthold R, Zempel J. GABA visualized by immunocytochemistry in the guinea pig cochlea in axons and endings of efferent neurons.  Brain Res. 1986;  366 106-117
    CrossrefPubMedGoogle Scholar
  • 26 Fitzgerald J D. Pentagastrin as a stimulant of maximal gastric acid response in man.  Lancet. 1967;  1(7485) 291-295
    PubMedGoogle Scholar
  • 27 Gorman J M, Liebowitz M R, Fyer A J, Stein J. A neuroanatomical hypothesis for panic disorder.  Am J of Psychiatry. 1989;  146 148-161
    PubMedGoogle Scholar
  • 28 Harro J, Vasar E, Bradwejn J. CCK in animal and human research on anxiety.  Trends Pharmacol Sci. 1993;  14 244-249
    CrossrefPubMedGoogle Scholar
  • 29 Harro J, Vasar E, Koszycki D, Bradwejn J. Cholecystokinin in panic and anxiety disorders.  Adv Biol Psychiatry. 1995;  1 235-262
    PubMedGoogle Scholar
  • 30 Hendry S, Jones E, DeFelipe J, Schmochel D, Brandon C, Emson P. Neuropeptide-containing neurons of the cerebral cortex are also GABAergic.  Proc Natl Acad Sci. 1984;  81 6526-6530
    PubMedGoogle Scholar
  • 31 Javanmard M, Shlik J, Kennedy S H, Vaccarino F J, Houle S, Bradwejn J. Neuroanatomic correlates of CCK- 4-induced panic attacks in healthy humans: a comparison of two time points.  Biol Psychiatry. 1999;  45 872-822
    CrossrefPubMedGoogle Scholar
  • 32 Knott V J, Lapierre Y D. Effects of lactate-induced panic attacks on brain stem auditory evoked potentials.  Neuropsychobiology. 1986;  16 9-14
    PubMedGoogle Scholar
  • 33 Knott V J, Bakish D, Barkley J. Brainstem evoked potentials in panic disorder.  J Psychiatry and Neurosci. 1994;  19 301-306
    PubMedGoogle Scholar
  • 34 Levy D, Kimhi R, Barak Y, Demmer M, Harel M, Elizur A. Brainstem auditory evoked potentials of panic disorder pateints.  Neuropsychobiology. 1996;  33 164-167
    PubMedGoogle Scholar
  • 35 Liebowitz M R, Gorman J M, Fyer A, Dillon D, Levitt M, Klein D F. Possible mechanisms for lactate’s induction of panic.  Am J Psychiatry. 1986;  143 495-502
    PubMedGoogle Scholar
  • 36 McDonald A, Pearson J. Coexistence of GABA and peptide immunoractivity in non-pyramidal neurons of the basolateral amygdala.  Neuroscience Lett. 1989;  100 53-58
    CrossrefPubMedGoogle Scholar
  • 37 Noble F, Roques B P. CCK-B receptor: chemistry, molecular biology, biochemistry and pharmacology.  Prog Neurobiology. 1999;  58 349-379
    PubMedGoogle Scholar
  • 38 Papp L A, Klein D F, Martinez J, Schneier F, Cole R, Liebowitz M, Hollander E, Tyer A, Jordan E, Gorman J. Diagnostic and substance specificity or carbon dioxide-induced panic.  Am J Psychiatry. 1993;  150 250-257
    PubMedGoogle Scholar
  • 39 Parnaud C, Eybalin M, Geffard M, Pujoi R. Light and electron microscopic localization of GABA- immunostraining in efferent fibres of the organ of Corti.  Neurosci Lett Suppl. 1986;  26 S284
    PubMedGoogle Scholar
  • 40 Picton T, Hilliard S, Krausz H, Galambos R. Human auditory evoked potentials. I: Evaluation of components.  Electroencephalogy Clin Neurophysio. 1974;  36 179-190
    CrossrefPubMedGoogle Scholar
  • 41 Pohl R, Yeragani V K, Balon R, Rainey J, Lycaki H, Ortiz A, Berchou R, Weinberg P. Isoproterenol-induced panic attacks.  Biol Psychiatry. 1988;  24 891-902
    CrossrefPubMedGoogle Scholar
  • 42 Pyke R E, Greenberg H S. Norepinephrine challenges in panic patients.  J Clin Psychopharmacol. 1986;  6 279-285
    PubMedGoogle Scholar
  • 43 Rehfeld J F, Nielson F C. Molecular forms and regional distribution of cholecystokinin in the central nervous system. In Bradwejn J, Vasar E (eds) Cholecystokinin and anxiety: from neuron to behavior. Springer Verlag Austin; 1995
    Google Scholar
  • 44 Shlik J, Vasar E, Bradwejn J. Cholecystokinin and psychiatric disorders. Role in aetiology and potential of receptor antagonists in therapy.  CNS Drugs. 1997;  8 134-152
    PubMedGoogle Scholar
  • 45 Shlik J, Koszycki D, Bradwejn J. Decrease in short-term memory ufnction induced by CCK-4 in healthy volunteers.  Peptides. 1998;  19 969-975
    CrossrefPubMedGoogle Scholar
  • 46 Shlik J, Zhou Y, Koszycki D, Vaccarino F J, Bradwejn J. Effects of CCK-4 infusion on the acoustic eye-blink startle and psychophysiological measures in healthy volunteers.  J Psychopharmacol. 1999;  13 385-390
    PubMedGoogle Scholar
  • 47 Somogyi L, Hodgson A, Smith A, Nunzi M, Gorio A, Wu J. Different populations of GABA-ergic neurons in the visual cortex and hippocampus of CAT contain somatostalin or cholecystokinin-immunoreactive material.  J Neursci. 1984;  4 2590-2603
    PubMedGoogle Scholar
  • 48 Thompson G, Cortez A, Lam D. Localization of GABA immunoreactivity in the auditory brainstem of guinea pigs.  Brain Res. 1985;  339 119-122
    CrossrefPubMedGoogle Scholar
  • 49 van Megan H JGM, Westenberg H GM, den Boer J A, Haigh J RM, Traub M. Pentagastrin induced panic attacks: enhanced sensitivity in panic disorder patients.  Psychopharmacology. 1994;  114 449-455
    PubMedGoogle Scholar
  • 50 van Megan H JGM, Westenberg H GM, Den Boer J A, Kahn R S. The panic-inducing properties of the cholecystokinin tetrapeptide CCK-4 in patients with panic disorder.  Eur Neuropsychopharmacol. 1996;  6 187-194
    PubMedGoogle Scholar
  • 51 Vetter D, Adams J, Mirgiaini E. A dual efferent GABAergic projection to the rat cochlea.  Soc Neurosci Ab. 1986;  12 979
    PubMedGoogle Scholar
  • 52 Westerberg B, Roberson J, Stach B. A double-blind placebo-controlled trial of baclofen in the treatment of tinnitus.  Am J Otol. 1996;  17 896-903
    PubMedGoogle Scholar
  • 53 Yeudall L, Schopflocher D, Sussman P, Barabash W, Warneke L, Gill D, Oho W, Howarth B, Tormanson P. Panic attack syndrome with and without agoraphobia: neuropsychological and evoked potential correlates. In Flor- Henry P, Gruzedier J (eds) Laterality and psychopathology Elsevier New York; 1983
    Google Scholar
  • 54 Gormon J, Kent J, Sullivan G, Coplan J. Neuroanatomical hypothesis of panic disorder, revised.  Am J Psychiatry. 2000;  157 493-505
    CrossrefPubMedGoogle Scholar
  • 55 Tsutsumi T, Akiyoshi J, Hikichi T, Kiyota A, Kohno Y, Katsurasi S, Yamamoto Y, Isogawa K, Nagayama H. Suppression of conditional fear by administration of CCKB receptor antisense oligodeoxynucleotide into the lateral ventricle.  Pharmacopsychiatry. 2001;  6 232-237
    Article in Thieme ConnectPubMedGoogle Scholar

Dr. Verner Knott

Royal Ottawa Hospital

1145 Carling Avenue

Ottawa, Ontario, K1Z 7K4

Canada

Phone: 613-722-6521 (ext. 6843)

Fax: 613-722-5048

Email: vknott@rohcg,on.ca